melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery metabolic

Euglycemic/Hyperinsulinemic Clamp Study
The hyperinsulinemic/euglycemic clamp is a standard method for detecting insulin receptor sensitivity and glucose utilization in experimental animals and in the clinic. In this model, insulin is infused intravenously (IV) at a steady rate and blood glucose levels maintained by variable infusion of glucose. At steady-state, the glucose infusion rate (GIR) is equal to tissue glucose uptake. Drugs, such as the thiazolidinones (PPARγ agonists; e.g. rosiglitazone) increase GIR in animals subjected to the euglycemic clamp and this increase in glucose utilization is driven by increased insulin receptor sensitivity.

                      

The data above illustrate how rosiglitazone-treated animals require a significantly higher rate of glucose infusion to maintain steady glucose levels relative to vehicle treated animals. Data are mean ± SEM; ***p<0.001 compared to vehicle.

 

If you are interested in learning more about the Euglycemic/Hyperinsulinemic Clamp Study, please contact models@meliordiscovery.com to start the conversation.